Skip to content

Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.

Powered by THEMA

Current Report · Items 2.02, 9.01 · 8-K

Pfizer Inc.

PFENYSEEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On August 4, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.…

Filed Aug 4, 2026Accepted Aug 4, 2026, 7:02 AM EDTCIK 78003Accession 0000078003-26-000094

View company →Permanent SEC source ↗

Press release in this filing

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance →

Company context

Current securities

PFENYSE · EQUITY · Current

Recent company filings

Registered securities in this filing

PFIZER INC · 8-K · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.05 par value

Symbol: PFE
Exchange: NYSE
Classification: COMMON
Status: Current

Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

1.000% Notes due 2027

Symbol: PFE/27
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

2.875% Notes due 2029

Symbol: PFE/29
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-4

Dimensions: us-gaap:StatementClassOfStockAxis

3.250% Notes due 2032

Symbol: PFE/32
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-5

Dimensions: us-gaap:StatementClassOfStockAxis

3.875% Notes due 2037

Symbol: PFE/37A
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-6

Dimensions: us-gaap:StatementClassOfStockAxis

4.250% Notes due 2045

Symbol: PFE/45
Exchange: NYSE
Classification: DEBT

Filing context

Context: c-7

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000007800326000094 · 6 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition On August 4, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.